BR112022025700A2 - Formulações de anticorpo de activina a e métodos de uso das mesmas - Google Patents

Formulações de anticorpo de activina a e métodos de uso das mesmas

Info

Publication number
BR112022025700A2
BR112022025700A2 BR112022025700A BR112022025700A BR112022025700A2 BR 112022025700 A2 BR112022025700 A2 BR 112022025700A2 BR 112022025700 A BR112022025700 A BR 112022025700A BR 112022025700 A BR112022025700 A BR 112022025700A BR 112022025700 A2 BR112022025700 A2 BR 112022025700A2
Authority
BR
Brazil
Prior art keywords
activin
antibody
methods
formulations
antibody formulations
Prior art date
Application number
BR112022025700A
Other languages
English (en)
Portuguese (pt)
Inventor
Kamen Douglas
Graham Kenneth
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of BR112022025700A2 publication Critical patent/BR112022025700A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00113—Growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
BR112022025700A 2020-06-18 2021-06-18 Formulações de anticorpo de activina a e métodos de uso das mesmas BR112022025700A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063040589P 2020-06-18 2020-06-18
PCT/US2021/038016 WO2021257947A1 (en) 2020-06-18 2021-06-18 Activin a antibody formulations and methods of use thereof

Publications (1)

Publication Number Publication Date
BR112022025700A2 true BR112022025700A2 (pt) 2023-02-28

Family

ID=77168377

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022025700A BR112022025700A2 (pt) 2020-06-18 2021-06-18 Formulações de anticorpo de activina a e métodos de uso das mesmas

Country Status (13)

Country Link
US (1) US12472253B2 (enExample)
EP (1) EP4168038A1 (enExample)
JP (2) JP7850084B2 (enExample)
KR (1) KR20230026407A (enExample)
CN (1) CN116322768A (enExample)
AU (1) AU2021293577A1 (enExample)
BR (1) BR112022025700A2 (enExample)
CA (1) CA3183316A1 (enExample)
CL (1) CL2022003586A1 (enExample)
CO (1) CO2023000264A2 (enExample)
IL (1) IL299103A (enExample)
MX (1) MX2022016403A (enExample)
WO (1) WO2021257947A1 (enExample)

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0747045B2 (ja) 1986-10-15 1995-05-24 株式会社大協精工 積層した注射器用滑栓
JP3100727B2 (ja) 1992-01-23 2000-10-23 株式会社大協精工 変性ポリシロキサン組成物及び該組成物を被覆した衛生ゴム製品
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
JP3172057B2 (ja) 1995-04-05 2001-06-04 株式会社大協精工 ラミネートゴム栓
JP3512349B2 (ja) 1999-01-29 2004-03-29 株式会社大協精工 柱状ゴム要素の成形型
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US6659982B2 (en) 2000-05-08 2003-12-09 Sterling Medivations, Inc. Micro infusion drug delivery device
US6629949B1 (en) 2000-05-08 2003-10-07 Sterling Medivations, Inc. Micro infusion drug delivery device
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
JP2002209975A (ja) 2001-01-19 2002-07-30 Daikyo Seiko Ltd 医薬バイアル用ラミネートゴム栓
UA115789C2 (uk) 2012-09-05 2017-12-26 Трейкон Фармасутікалз, Інк. Композиція антитіла до cd105 та її застосування
TWI655207B (zh) 2013-07-30 2019-04-01 再生元醫藥公司 抗活化素ａ之抗體及其用途
US20160075772A1 (en) * 2014-09-12 2016-03-17 Regeneron Pharmaceuticals, Inc. Treatment of Fibrodysplasia Ossificans Progressiva
US20180008672A1 (en) * 2016-07-08 2018-01-11 Regeneron Pharmaceuticals, Inc. Anti-activin a antibodies and methods of use thereof for treating pulmonary arterial hypertension
CN109641954A (zh) 2016-08-29 2019-04-16 里珍纳龙药品有限公司 抗-gremlin-1(grem1)抗体及其用于治疗肺动脉高血压的使用方法
WO2018184692A1 (en) * 2017-04-07 2018-10-11 Ares Trading S.A. Liquid pharmaceutical composition
MX2020004756A (es) * 2017-11-16 2020-08-20 Novartis Ag Terapias de combinacion.
IL276921B2 (en) * 2018-03-01 2025-12-01 Regeneron Pharma Methods for altering body composition

Also Published As

Publication number Publication date
AU2021293577A1 (en) 2023-02-09
MX2022016403A (es) 2023-04-11
JP2026108880A (ja) 2026-06-30
EP4168038A1 (en) 2023-04-26
KR20230026407A (ko) 2023-02-24
CL2022003586A1 (es) 2023-07-21
CA3183316A1 (en) 2021-12-23
IL299103A (en) 2023-02-01
US20210393779A1 (en) 2021-12-23
WO2021257947A1 (en) 2021-12-23
CO2023000264A2 (es) 2023-01-26
CN116322768A (zh) 2023-06-23
JP7850084B2 (ja) 2026-04-22
JP2023532203A (ja) 2023-07-27
US12472253B2 (en) 2025-11-18

Similar Documents

Publication Publication Date Title
CY1123909T1 (el) Σταθεροποιημενα σκευασματα που περιεχουν αντισωματα κατα του υποδοχεα της ιντερλευκινης-6 (il-6r)
BR112021026414A2 (pt) Formulação compreendendo o anticorpo biespecífico anti-cd47/pd-l1, método para preparo e uso do mesmo
MA56289B1 (fr) Mutéines d'interleukine-21 et méthodes de traitement
BR112020004509A8 (pt) Conjugado polissacarídeo-proteína carreadora, composição imunogênica compreendendo o mesmo e uso do referido conjugado
CL2019003032A1 (es) Formulaciones de anticuerpos humanos anti-rankl y métodos de uso de estas.
BR112021022514A2 (pt) Conjugados de anticorpo e fármaco
BRPI0917470B8 (pt) anticorpo anti-lag-3 ou uma porção de ligação ao antígeno do mesmo, seu método de preparação, seus usos, composição, imunoconjugado, molécula de ácido nucleico isolado, vetor de expressão e método de estímulo de uma resposta de células t antígenoespecífica
CY1114185T1 (el) Υποδοριο σκευασμα αντισωματος αντι-her2
BR112015023520A2 (pt) purificação do conjugado de anticorpo-fármaco (adc)
BRPI1013780A2 (pt) composições para imunização contra staphylococcus aureus.
BR112023006024A2 (pt) Terapias de imuno-oncologia com conjugados de il-2
BR112021012056A2 (pt) Inibidor da expressão gênica do hbv, agente que reduz a carga antigênica de hbv, composições para uso no tratamento de uma infecção crônica por hbv, usos de um inibidor da expressão gênica do hbv e de um agente que reduz a carga antigênica de hbv, métodos de tratamento da infecção crônica por hbv e kit
NO20083104L (no) Fast preparat
BR112014028997A2 (pt) formulações estabilizadas contendo anticorpos anti-dll4
BR112021018727A2 (pt) Formulações estabilizadas que contêm anticorpos anti il 33
BR112021024491A8 (pt) Composição imunogênica, e, método para prevenir, tratar ou melhorar uma infecção, doença ou condição
BR112023014221A2 (pt) Composição compreendendo vesículas extracelulares derivadas de plantas manipuladas por engenharia e seu uso como uma vacina
BR112023001642A2 (pt) Bancos de células t específicos de antígeno universais e métodos de preparar e usar os mesmos automaticamente
CL2025001313A1 (es) Composiciones que contienen enzimas que escinden anticuerpos y métodos de uso de las mismas
BRPI0808599A2 (pt) "ácido nucléico, vacina, composição farmacêutica, uso de um ácido nucléico e método para estimular uma imunoresposta versus um epítopo das células t"
MX2024012664A (es) Formulaciones de arginina de alta concentracion estables que contienen anticuerpo pd-1 y metodos de uso de estas
BR112013026153A2 (pt) Composição farmacêutica; uso de pelo menos um éter de celulose não iônico; método parapreparar uma composição farmacêutica; método para tratar e/ou prevenir um distúrbioclimatérico; uso de uma composição farmacêutica; e kit
CL2013003307A1 (es) Agente que comprende ciazofamida o fenamidona; y su uso para tratar micosis en peces e invertebrados en todos sus estadios de desarrollo causada por hongos de los generos saprolegnia, achlya y aphanomyces (div.sol.n°1056-08).
BR112018074496A2 (pt) composição biopesticida para uso na prevenção minimização de doenças de plantas
BR112021021728A2 (pt) Conjugado de anticorpo anti-bcma, composições que compreendem os mesmos e métodos para fazer e usar os mesmos